EBR Systems (ASX:EBR), the pioneer behind the world's only wireless cardiac pacing device for heart failure, reported a robust first quarter for 2026, characterised by a dramatic acceleration in commercial adoption.
In a preliminary quarterly update released on April 9, the company revealed that case volumes for its proprietary WiSE System more than doubled compared to the previous quarter.
The surge was highlighted by 41 new commercial implants during Q1, bringing the total number of patients treated across the pilot and limited market release phases to 71.
Financial projections reflect this operational momentum, with EBR expecting to report Q1 revenue between US$2.5 million and US$2.4 million.
CEO John McCutcheon attributed the "impressive progress" to increasing physician experience and expanded site readiness.
The company’s LMR strategy continues to yield significant results, with 16 new purchase agreements signed during the period, bringing the total to 37.
Additionally, 22 new physicians were trained this quarter, raising the total number of qualified specialists to 55.
Beyond commercial success, EBR is advancing its clinical pipeline through the WiSE-UP post-approval study and the TLC-AU feasibility study.
The initiatives aim to broaden the evidence base and support a wider patient population.